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Epitopes on the surface of the foot-and-mouth disease virus (FMDV) capsid have been identified
by monoclonal antibody (mAb) escape mutant studies leading to the designation of four antigenic
sites in serotype A FMDV. Previous work focused on viruses isolated mainly from Asia, Europe and
Latin America. In this study we report on the prediction of epitopes in African serotype A FMDVs
and testing of selected epitopes using reverse genetics. Twenty-four capsid amino acid residues
were predicted to be of antigenic significance by analysing the capsid sequences (n556) using in
silico methods, and six residues by correlating capsid sequence with serum–virus neutralization
data. The predicted residues were distributed on the surface-exposed capsid regions, VP1–VP3.
The significance of residue changes at eight of the predicted epitopes was tested by site-directed
mutagenesis using a cDNA clone resulting in the generation of 12 mutant viruses involving seven
sites. The effect of the amino acid substitutions on the antigenic nature of the virus was assessed
by virus neutralization (VN) test. Mutations at four different positions, namely VP1-43, VP1-45,
VP2-191 and VP3-132, led to significant reduction in VN titre (P value50.05, 0.05, 0.001 and
0.05, respectively). This is the first time, to our knowledge, that the antigenic regions
encompassing amino acids VP1-43 to -45 (equivalent to antigenic site 3 in serotype O), VP2-191
and VP3-132 have been predicted as epitopes and evaluated serologically for serotype A FMDVs.
This identifies novel capsid epitopes of recently circulating serotype A FMDVs in East Africa.
INTRODUCTION
Foot-and-mouth disease (FMD) is a highly infectious,
rapidly spreading and internationally important livestock
disease. It has significant socio-economic consequences
due to losses in production and constraints on export of
live animals and associated products to disease-free
countries. FMD is caused by FMD virus (FMDV) that
belongs to the family Picornaviridae, genus Aphthovirus.
The virus exists as seven distinct serotypes (A, O, C, Asia1,
South African Territory (SAT)-1, SAT-2 and SAT-3) that
differ genetically and antigenically with multiple strains in
different continents. Globally, most outbreaks of FMD are
caused by serotype O followed in frequency by serotype A
(Rweyemamu et al., 2008; Chitray et al., 2014; Wekesa et al.,
2014), which is endemic in many developing countries of
Africa and Asia. FMDV serotype A continues to cause
outbreaks in East Africa (Bari et al., 2014; Wekesa et al.,
2014). It is a small, non-enveloped virus containing a
single-stranded positive-sense RNA genome. The genome
has a single ORF that encodes four capsid (structural)
proteins and 10 non-structural proteins (Grubman & Baxt,
2004). As an RNA virus, it is characterized by the frequent
emergence of new variants responsible for recurring disease
outbreaks.
The genetic heterogeneity of the FMDV arises from lack of
proofreading mechanisms during virus replication resulting
in new variants, including those with changes in antigen-
ically important sites of the virus (VP1-3) that may improve
viral fitness. These sites are commonly investigated in vitro
by epitope mapping using mAb (Thomas et al., 1988;
Bolwell et al., 1989; Kitson et al., 1990; Crowther et al., 1993;
Mateu et al., 1995; Mahapatra et al., 2011; Grazioli et al.,
2013). Four antigenic sites (equivalent to sites 1, 2, 4 and 5 of
serotype O) were described for serotype A; site 1 (G-H loop
of VP1) is linear and trypsin-sensitive, whereas the others are
One supplementary figure and one supplementary table are available
with the online Supplementary Material.
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conformational and trypsin-resistant (Thomas et al., 1988;
Bolwell et al., 1989; Saiz et al., 1991; Mahapatra et al., 2011).
Escape mutants are also studied using polyclonal antibodies
in serotypes O and C (Rojas et al., 1992; Schiappacassi et al.,
1995; Kumar et al., 2004; Sarangi et al., 2013). In addition,
the location of antibody binding sites (epitopes) can be
inferred from correlating the antibody cross-reactivity of
viruses to their capsid sequence similarities (Reeve et al.,
2010).
Epitopes can also be predicted from three-dimensional
(3D) structural data alone, from aligned sequence data
alone, or by using both sequence data and three-
dimensional structural data. More than 90% of B-cell
epitopes are conformational (Barlow et al., 1986), where
distantly located residues on a sequence come together
during protein folding, and prediction of these epitopes is
better performed by combining structural and sequence
information. Various structure-based epitope prediction
programs are available freely (Rubinstein et al., 2009;
Kringelum et al., 2012; Qi et al., 2014). DiscoTope
(Kringelum et al., 2012), for example, uses a combination
of statistical difference in amino acid composition between
epitope and non-epitope residues, structural proximity
and physico-chemical properties of neighbourhood amino
acids, and a surface measure. All structure-based methods
retrieve data from the protein database (PDB) file and
conduct BLAST searches for closely related sequences.
DiscoTope, Epitopia and SEPPA were recently applied to
FMDV epitope prediction by Borley et al. (2013).
The importance of predicted residues for antibody binding
can be tested by introducing specific mutations into a
cDNA clone of the virus of interest. This approach is
widely applied in emerging virus investigations including
those into influenza (Yang et al., 2013), FMDV (Blignaut
et al., 2011; Asfor et al., 2014; Opperman et al., 2014) and
human immunodeficiency virus type 1 (HIV-1) (Evans
et al., 2014).
Epitopes of many FMDV serotype A strains originating
from Asia, Europe and Latin America are well charac-
terized using monoclonal antibody resistant (mar) studies
(Thomas et al., 1988; Baxt et al., 1989; Saiz et al., 1991;
Mahapatra et al., 2011). However, there are no reports for
analysis of epitopes using serotype A isolates originating
from East Africa. In this study, we studied viruses from
East Africa and report prediction of epitopes, including
amino acid residues not reported previously for serotype A
viruses. Eight of the predicted epitopes were tested using a
cDNA clone and their antigenic impact was assessed by virus
neutralization (VN) test, revealing neutralizing epitopes at
positions VP1-43, -45, VP2-191 and VP3-132.
RESULTS AND DISCUSSION
Antibodies play an important role in conferring protection
against FMDV, including the protective effect of vaccin-
ation (Pay and Hingley, 1987; McCahon et al., 1989),
which is derived from antibodies directed towards the
surface of the inactivated capsids. Identification of the
epitopes and understanding their immunodominance in
antigenically and genetically diverse FMDVs is of utmost
importance for vaccine strain selection and novel vaccine
development to achieve adequate protection against the
disease (Doel, 1996; Paton et al., 2005; Parida, 2009).
Epitope prediction
Studies on the critical amino acid residues for neutraliza-
tion of serotype A FMDV have used mainly mar-mutant
approaches with viruses from the Middle East (A22)
(Bolwell et al., 1989), India (A/IND/17/77) (Tosh et al.,
1999), Europe [A5 (Saiz et al., 1991), A10 (Thomas et al.,
1988), A12 (Baxt et al., 1989)] and South America (A24)
(Mahapatra et al., 2011). Consequently, there is no
information available on the epitopes present on the serotype
A viruses isolated from Africa. Therefore, as an initial step,
we analysed a collection of East African serotype A viruses (i)
by using two freely available software programs to predict
epitopes from capsid amino acid sequences with and without
structural information [in this case, the A1061 PDB file
(1ZBE)] and (ii) by correlating differences in neutralizing
serum titres between virus pairs with capsid amino acid
sequence changes.
Epitopes predicted by in silico methods. The results of
Shannon entropy and ConSurf analysis are presented in
Table 1. High Shannon entropy signifies amino acid
variability and high values have been reported for variable
epitopes in HIV (Liu et al., 2013; Evans et al., 2014),
influenza (Pan & Deem, 2011) and neutralization escape
FMD viruses (Piatti et al., 1995; Maree et al., 2011). In
Shannon entropy analysis, use of a threshold of 0.86 (half of
the highest score) resulted in the selection of 33 candidate
amino acid residues to be of antigenic significance.
The highest antigenicity score in ConSurf was 5.29 and the
top scoring 33 amino acid positions were compared with
the entropy prediction results. Out of these, 24 were
selected by both methods showing good agreement (86%)
between the two prediction methods (Fig. 1). All the 24
predicted residues were located on the outer surface of the
virus capsid (Fig. 2b) except two residues, VP2-207 and
VP3-35, which were internal (Fig. 2c). Eleven, eight and
five predicted residues are present in VP1, VP2 and VP3,
respectively (Table 1). Out of these, seven (29.2%) have
been previously reported in serotype A viruses; VP1-139/
141/142, -149 (Thomas et al., 1988), VP1-198 (Saiz et al.,
1991), VP3-70 (Thomas et al., 1988) and VP2-134 were
reported to be of antigenic significance in serotype A
viruses previously (Saiz et al., 1991) or to influence mAb
binding in serotype O (Mahapatra et al., 2008). Previously,
in silico epitope predictions performed using the A1061
crystal structure identified six (VP1-196/197/198, VP2-191
and VP3-70/71) of the 24 residues (Borley et al., 2013).
Because ConSurf predicts epitopes with reference to the 3D
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Table 1. List of capsid amino acid residues and their scores from entropy and ConSurf analysis
Amino acids are arranged according to their order in the P1 sequence. The predicted amino acid residues are mostly located close to known
epitopes except for residue VP2-191 that is 5 aa apart from VP2-196. NR, No reference antigenic site reported; GHL, VP1 G-H loop.
P1 position Viral protein
(VP)
VP position Entropy value ConSurf score Epitope reported
previously
Residue located on external
surface
159 2 74 1.1 3.985 NR Yes
163 2 78 1.156 4.458 NR Yes
171 2 86 1.183 4.472 NR Yes
173 2 88 0.867 3.644 NR Yes
218 2 133 1.37 4.662 NR Yes
219 2 134 1.704 4.802 134 Yes
276 2 191* 1.627 4.789 NR Yes
292 2 207 1.018 3.65 NR No
338 3 35 0.988 3.523 NR No
373 3 70 1.031 4.541 70 Yes
374 3 71 1.348 5.29 71 Yes
434 3 131* 0.931 3.074 NR Yes
523 3 220* 1.25 5.034 NR Yes
566 1 42 1.096 2.529 NR Yes
567 1 43* 1.222 2.996 NR Yes
568 1 44* 1.42 3.555 NR Yes
569 1 45* 1.554 3.861 NR Yes
623 1 99 1.585 4.287 NR Yes
625 1 101 1.078 2.38 NR Yes
663 1 139 1.177 2.855 139 GHL
666 1 142 1.185 2.915 142 GHL
673 1 149 1.263 3.132 149 GHL
721 1 197 1.484 3.783 NR Yes
722 1 198 1.343 3.3 198 Yes
*Residues selected for site-directed mutagenesis study.
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Fig. 1. Scatter plot of Shannon entropy and ConSurf values showing areas of concordant high values (top right box, B)
corresponding to the 24 commonly predicted amino acids. The cut-off values are indicated by black dotted lines. The high R2
value (86.1%) indicates good correlation of the two prediction results. The graph was drawn using Minitab V.16 statistical software.
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structure and also by comparing evolutionary conservation
rates of the aligned amino acid sequences, it is expected
that it might provide more specific predictions of epitopes
than would entropy analysis. Accordingly, ConSurf selected
VP1-148 (data not shown), a neutralizing conformational
epitope reported earlier for serotype A (Mahapatra et al.,
2011).
This is the first report, to our knowledge, to predict that
residues at VP1-43/44/45 could have potential antigenic
significance in serotype A FMDV. In addition, the
neighbouring residue VP1-46 is also highly variable and
together they form a cluster of residues on the capsid
surface. Many of the previously identified regions of high
amino acid variability on the P1 sequence of serotypes A
and O FMDVs correspond to known antigenic sites and
these positions are conserved structurally between the two
serotypes (Fry et al., 2005; Chitray et al., 2014). This region
corresponds to antigenic site 3 in serotype O (Kitson et al.,
1990). In serotype O the stability of antigenic site 3 has
been considered important for the stability of the VP1 G-H
loop, and any destabilization in VP1 residues 43 to 45 may
distort the conformation of the flexible VP1 G-H loop (Fry
et al., 2005). Opperman et al. (2014) also recently reported
the binding of monoclonal antibodies to closely located
residues VP1-48 to -50 in the SAT2 serotype of FMDV. In
addition, both ConSurf and entropy analysis predicted
VP1-99 and -101 to be of antigenic significance whilst VP1-
110 was predicted by entropy analysis only. A recent study
in SAT2 FMDVs also suggested the presence of epitopes
at VP1-109 and -111 (Opperman et al., 2014). In VP2, of
the eight residues predicted by both methods only two
(VP2-134 and VP2-191) were indicated to be of antigenic
significance. The remaining six residues were newly
predicted (Table 1) in silico to be of antigenic importance
but their relevance so far could not be confirmed by other
methods. The amino acid at position VP2-191 is located at
the threefold axis of the capsid and is among the top four
amino acids predicted by both in silico methods. This
residue has been recently reported to be a neutralizing
epitope linked to antigenic site 2 in serotype O FMDV
(Asfor et al., 2014). In VP3, a total of five residues were
predicted of which three (35, 71 and 131) were newly
predicted. VP3-70 was previously reported by mar-mutant
studies (Thomas et al., 1988). Recently, VP3-220 has been
indicated to be of antigenic significance in serotype A viruses
(Upadhyaya et al., 2014) and is located close to other newly
predicted residues (VP1-99 and VP1-101) on the outer
surface of the capsid (Fig. 2b).
Epitopes predicted by correlating sequence and
serology data. A total of six residues were predicted as
epitopes by correlating serum titres and changes in capsid
amino acid sequences, namely residues VP1-81, -138, -148
and -159, VP2-79 and VP3-132. Of these, four residues,
VP1-138, -159 (Thomas et al., 1988), VP1-148 (Mahapatra
et al., 2011) and VP2-79 (Saiz et al. 1991), were reported
previously using mar-mutant studies or are within the VP1
G-H loop. Though VP3-135 has been reported by mar-
mutant studies in SAT1 virus (Grazioli et al., 2006),
residues VP1-81 and VP3-132 have not been reported
previously in serotype A viruses and were good candidates
for further investigation using a cDNA clone.
Among all the epitopes predicted by the in silico methods,
residue VP2-191 was among the top four predicted
epitopes and has not been reported previously by mar-
mutant studies. VP1-43, -44 and -45, equivalent to antigen
site 3 in serotype O virus, was predicted by both the in
silico methods and was therefore selected for further
investigation. In addition, the epitopes at VP1-81 and
VP3-132 uniquely predicted by correlating sequence and
serology data were taken forward for further investigation.
VP3-131 predicted by ConSurf is located next to VP3-132
on the external surface and was taken forward for further
investigation. VP3-220 predicted by both the in silico
methods was also selected for further investigation.
Generation of full-length genome plasmids
The capsid-coding region of serotype A FMDV (A-EA-2007)
was cloned successfully into the plasmid pT7S3-O1Kwt to
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Fig. 2. A1061 (1ZBE) structure showing (a) the critical residues of reported epitopes; epitopes predicted in this study (b)
external surface, (c) internal surface. Red, green and blue colours indicate residues in VP1, VP2 and VP3, respectively.
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generate the full-length genome plasmid pT7S3/A-EA-2007.
This plasmid was used as the template to introduce further
mutations in the capsid-coding region. A total of eight
residues (VP1-43, -44, -45, -81, VP2-191 and VP3-131, -132,
-220) were selected for this purpose as they were indicated
to have an impact on the antigenicity of the virus by
comparison of capsid sequences with in vitro virus cross-
neutralization data or by epitope prediction using capsid
sequence and viral crystal structure, and were novel (not
reported previously). A total of 12 single mutant plasmids
involving seven residues were generated (Table 2). The
capsid coding regions of all the plasmids were sequenced on
both strands and no unwanted mutations were observed.
Rescue and characterization of recombinant
viruses from full-length genome plasmids
Live infectious viruses were recovered successfully from
all the cDNA clones following electroporation. FMDV-
specific cytopathic effect (CPE) was observed 18–24 h
post-electroporation. Extensive CPE was observed at both
the first and second passages. At least two independent
clones of each virus were rescued. However, only one clone
in each case was used for further characterization. In order
to establish that the expected viruses had been rescued,
reverse transcription (RT)-PCR was carried out on the
RNA extracted from infected BHK-21 cells using primer
pair L460F and EUR2B52R/NK72 that produced a 2500 bp
fragment (encompassing C-terminal part of L, P1, 2A and
N-terminal part of 2B) of expected size (data not shown).
No PCR products were generated in parallel reactions in
which the enzyme reverse transcriptase was omitted,
indicating that the products amplified were not generated
from the transfected plasmid DNA. The PCR products
were sequenced on both the strands and no additional
nucleotide substitutions were observed in any of the
mutants generated in this study.
The parent virus A-EA-2007 represents genotype VII of
serotype A FMDV circulating in East Africa. Previously,
chimeric viruses containing capsid-coding regions derived
from serotype A/Turkey 2/2006 or O/UKG/34/2001 FMDV
with the backbone of serotype O1K cDNA clone (pT7S3-
O1K) have been generated successfully (Bøtner et al.,
2011). These chimeric viruses retained the characteristics
(in terms of receptor utilization, antigenicity, pathogen-
icity, etc.) from the parent from which the capsid was
derived. In addition, successful switching of capsids from
other serotypes of FMDV for the purpose of recombinant
vaccine development and evaluation has been reported
(van Rensburg et al., 2004; Blignaut et al., 2011; Zheng
et al., 2013).
The mutants were stable genetically at least up to third
passage as confirmed by full capsid sequencing. Standard
multi-step growth curves were carried out to compare the
growth of the recombinant viruses with that of the parent
virus. All the viruses grew at a similar rate and to a similar
titre, indicating the mutations in the antigenic sites had no
adverse effects on the replication efficiency of these viruses
in vitro (Fig. S1, available in the online Supplementary
Material). The ability of FMDVs to tolerate changes at
these positions is consistent with the observation of high
amino acid variability at these residue positions in the 115
field viruses analysed [56 sequences reported before those
of Bari et al. (2014) and the remaining 59 sequences
downloaded from GenBank; data not shown]. BHK-21
cells infected with the parent or recombinant viruses were
stained following infection and photographed. Both the
Table 2. List of O1K/A-EA-2007 mutant viruses generated in this study and their associated amino acid substitutions
Positions different from rO1K/A-EA-2007 are shaded.
Virus Capsid amino acid substitutions
VP1 VP2 VP3
43 44 45 191 131 132 220
rO1K/A-EA-2007 N S L T E T Q
rO1K/A-EA-2007M1 A S L T E T Q
rO1K/A-EA-2007M2 N A L T E T Q
rO1K/A-EA-2007M3 N P L T E T Q
rO1K/A-EA-2007M4 N S P T E T Q
rO1K/A-EA-2007M5 N S L A E T Q
rO1K/A-EA-2007M6 N S L D E T Q
rO1K/A-EA-2007M7 N S L T A T Q
rO1K/A-EA-2007M8 N S L T D T Q
rO1K/A-EA-2007M9 N S L T E A Q
rO1K/A-EA-2007M10 N S L T E S Q
rO1K/A-EA-2007M11 N S L T E T A
rO1K/A-EA-2007M12 N S L T E T T
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parent and the recombinant viruses exhibited variable size
plaques with no clear differences between them (data not
shown). This corroborates the findings in a recent study of
serotype O FMD mutant viruses (Seago et al., 2012;
Lawrence et al., 2013; Asfor et al., 2014).
Serological reactivity of rO1K/A-EA-2007 mutant
viruses
The impact of the amino acid substitutions on sero-
reactivity was assessed by VN test using the pooled post-
vaccination serum (bovine) raised against rO1K/A-EA-
2007 antigen. The main goal was to quantify the reduction
in neutralization following mutations in the capsid of
FMDV. Therefore, it was crucial to determine the VN titre
of the sera against all the mutant viruses at a fixed virus
dose (100 TCID50). Therefore, a two-dimensional micro-
neutralization test (2D-VNT) was carried out using five
different doses of the virus encompassing 100 TCID50 for
this purpose. The resultant VN titres at each virus dose
were used to calculate the serum titre at 100 TCID50 by
regression analysis. Because getting consistent results was
very important for the evaluation of the mutant viruses,
each test was conducted in duplicate and repeated at least
eight times. Test results showing evidence of a reduction in
serum titre after mutagenesis were repeated eight more
times for further confirmation. Among the 12 mutants
generated in this study, only five mutants, i.e. rO1K/A-EA-
2007M1 (VP1-L43A), rO1K/A-EA-2007M4 (VP1-L45P),
rO1K/A-EA-2007M5 (VP2-T191A), rO1K/A-EA-2007M6
(VP2-T191D) and rO1K/A-EA-2007M10 (VP3-T132S),
exhibited significant reductions in serum titre (Fig. 3).
The substitution of threonine at VP2-191 to alanine or
aspartic acid exhibited relatively greater (15% and 12.5%,
respectively) reductions in serum titre as compared with
the parent virus. This agrees with the report of Crowther
et al. (1993) who reported ~15% reduction in serum titre
as a result of a single amino acid change. In line with this,
recently, Asfor et al. (2014) evaluated this epitope for
serotype O FMDV using a cDNA clone and reported ~30%
reduction in serum titre. Hence this residue could
represent a novel epitope across several serotypes. The
residues VP1-43 to -45 are in an equivalent position to
antigenic site 3 in serotype O (Kitson et al., 1990). Though
mar-mutant studies have been carried out in several type A
viruses, this region has never been reported to be of
antigenic significance. However, VP1-45 has been indicated
to impact on the antigenic nature of the serotype A viruses
from the Middle East (Jamal et al., 2011; Upadhyaya et al.,
2014). In addition, analysis of 115 serotype A capsid
sequences revealed amino acids VP1-42 to -46 to be highly
variable (data not shown). The substitution of threonine at
position VP3-132 led to significant reduction in serum titre
whereas substitution to alanine did not have much impact,
indicating certain residue changes are more powerful than
others. Mutations in epitopes may also have the opposite
effect, i.e. neutralizing titres may increase after mutation of
capsid residues. In fact, Opperman et al. (2014) reported
significantly higher VN titres in SAT epitope-replaced
mutants that were related to higher avidity index. However,
we did not observe significantly higher VN titre in the
mutant viruses in this study. In our previous study on
serotype O epitope mutants (Asfor et al., 2014) we also did
not observe higher VN titre than the homologus virus. This
could be due to a different serotype or strain of the virus.
In conclusion, we have predicted epitopes for serotype A
viruses from Africa and tested a new epitope/antigenic site
(VP1-43/45) for serotype A FMDVs that is equivalent to
antigenic site 3 in serotype O. Substitution of threonine
(amino acid found in genotype IV viruses) at position
VP2-191 with either alanine or aspartic acid confirmed the
antigenic significance of this residue as well as mutations at
VP1-43, VP1-45 and VP3-132. These residues are novel
epitopes that have not been reported previously for
serotype A FMDVs.
METHODS
Viruses, cells and plasmid. The 56 East African type A viruses and
their corresponding capsid sequences and serology data against seven
vaccine strains described previously (Bari et al., 2014) were used in
this study. IB-RS2 cells (a pig kidney cell line) were used for growing
viruses, titration and VN test. BHK21 cells were used for electro-
poration and passaging of recombinant viruses.
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Fig. 3. Percentage reduction in serum titre of selected rO1K/A-
EA-2007 mutant viruses that showed significant reduction in
serum titre compared with the parent rO1K/A-EA-2007 virus. 2D-
VNT was carried out using bovine serum raised against rO1K/A-
EA-2007 viral antigen. Error bars indicate SD for the respective
mutant. The significance of the test differences were calculated
from a total of 16 repeats except for rO1K/A-EA-2007M6 for
which only 12 VN test results were used. * and *** indicate
significant difference (from parent rO1K/A-EA-2007 virus) at
P,0.05 and P,0.001, respectively.
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The most broadly reactive vaccine strain, A-EA-2007 (Bari et al.,
2014), was selected for the reverse genetics work in this study. The
parental virus was plaque-purified four times on IB-RS2 cells. An
existing serotype O infectious copy of FMDV (pT7S3-O1Kwt)
containing unique restriction sites at the beginning and end of the
capsid-encoding genes (AflII and SpeI restriction sites in the L and 2B
regions of the FMDV genome, respectively; Asfor et al., 2014) was
used for this study.
RNA extraction, RT-PCR and sequencing. Total RNA was
extracted from cell-culture-grown viruses using RNeasy Mini kits
(Qiagen) according to the manufacturer’s recommendation. Reverse
transcription (RT)-PCR to amplify the capsid-coding region,
nucleotide sequencing and sequence analysis were carried out as
described by Upadhyaya et al. (2014).
Construction of recombinant full-length genome plasmid.
Standard molecular biological techniques were used for the cloning
of the serotype A capsid into vectors. The A-EA-2007 FMDV capsid-
encoding region was amplified from the total RNA isolated from the
plaque-purified virus using specific primer set A-EA-2007 AflII F/A-
EA-2007SpeI R containing AflII and SpeI restriction sites, respectively
(Table S1). The amplified product was cloned in to the intermediate
vector pT7Blue (Promega) resulting in generation of pT7Blue-A-EA-
2007. The capsid was excised from the intermediate vector using AflII
and SpeI restriction enzymes. The excised capsid-encoding region was
used to replace the capsid-encoding region of pT7S3-O1Kwt to
generate pT7S3-O1K/A-EA-2007. The capsid-encoding region of the
full-length genome plasmid was sequenced on both the strands to
ensure they were from the desired virus. pT7S3-O1K/A-EA-2007 was
used in all subsequent experiments.
Epitope prediction.
In silico methods. Two different methods of epitope prediction, (a)
Shannon entropy (Shannon, 1948) and (b) conservation surface
mapping (ConSurf) (Landau et al., 2005; Ashkenazy et al. 2010), were
used to predict candidate epitopes from the capsid sequence data of
56 serotype A FMDVs originating from Africa (Bari et al., 2014). The
Shannon entropy analysis implemented in BioEdit v7.2.5 (Hall, 1999)
was used to calculate the variability of each amino acid position
across all VP1-3 sequences taking account of the type and frequency
of amino acids. In Shannon entropy, a score more than half of
the highest score was used as a cut-off to select the most variable
residue. In ConSurf (http://consurf.tau.il), the prediction of epitopes
was performed by calculating the evolutionary conservation rate
(inverse of evolutionary substitution rate) using a Bayesian method
(Ashkenazy et al. 2010) for each position in the multiple amino acid
sequence alignments of individual VP regions (VP1-3). The three-
dimensional crystal structure of serotype A1061 FMDV (Fry et al.,
2005) was used as the reference structure. ConSurf also predicts the
location of each amino acid (buried or surface exposed) and assigns
an antigenicity score.
By correlating capsid sequence with serology data. The locations
of residues involved in antibody binding sites (epitopes) were inferred
by correlating the antibody cross-reactivity of viruses to their capsid
sequence similarities as described previously (Reeve et al., 2010). This
technique identifies residues responsible for cross-reactivity while
controlling for repeated measures arising from the phylogenetic
relationship between the viruses. The capsid sequence data of 56 East
African type A viruses and their corresponding serology data against
seven vaccine strains (Bari et al., 2014) were used for this analysis.
Construction of mutant plasmids. Standard site-directed muta-
genesis (SDM) technique was used to introduce mutations at specific
positions in the capsid of pT7S3-O1K/A-EA-2007. A total of eight
sites (VP1-43/44/45/81; VP2-191, VP3-131/132/220), all in surface-
exposed capsid regions and newly predicted (not previously
reported), were selected for further investigation. These residues were
substituted either to alanine or with a specific amino acid whose
presence in other isolates had been correlated with higher or lower
antibody reactivity. Specific overlapping primers were designed to
introduce mutations either individually or in combinations to make
recombinant viruses containing either single or double substitutions
in the capsid (Table S1). The cDNA backbone containing the serotype
A capsid was manipulated according to the method described by
Asfor et al. (2014). The capsid-encoding regions of all the plasmids
were sequenced to confirm the identity of the mutations introduced.
Electroporation and rescue of recombinant viruses. The parent
plasmid (pT7S3-O1K/A-EA-2007) or its derivatives were linearized by
digestion with HpaI enzyme and full-length RNA transcripts were
synthesized as described previously (Asfor et al., 2014). Electropor-
ation of the transcribed RNA and recovery of the recombinant viruses
were also carried out as described previously (Asfor et al., 2014). The
rescued viruses were subsequently passaged at least three times before
stocks of viruses were made.
Characterization of recombinant viruses. In order to characterize
the recombinant viruses, RT-PCR was carried out on the total RNA
isolated from virus-infected BHK-21 cells. The whole capsid was
amplified and then sequenced on both strands to ensure all the
mutations were present in the respective viruses. Virus titres for each
virus were determined on IB-RS2 cells as described by Reed &
Muench (1938). The growth kinetics of the mutant and parental
recombinant viruses were evaluated as described by Asfor et al.
(2014). The plates were frozen at five different time points (0, 4, 8, 12
and 24 h) post-infection. The harvested virus was stored at 270 uC
until used. The plaque sizes of the mutant and the parent
recombinant viruses were also compared, as described by Asfor et al.
(2014).
Generation of polyclonal sera against rO1K/A-EA-2007 vaccine
in cattle. For use in serological assays antisera were prepared in cattle
against the recombinant parent virus recovered from the cDNA clone
(rO1K/A-EA-2007), which is the parent to all other mutant viruses
generated in this study. Briefly, the rO1K/A-EA-2007 virus was
grown in BHK-21 cells. When the CPE was complete, the culture
supernatant was harvested, clarified by centrifugation, and inactivated
with 5 mM binary ethylenimine (BEI) at 25 uC for 24 h (Bahnemann,
1975, 1990). The inactivated antigen was purified by sucrose gradient
purification (Ferris et al., 1984) and concentrated by polyethylene
glycol precipitation. The vaccine was prepared from the antigen as a
water-in-oil-in-water emulsion with Montanide ISA 206 (SEPPIC)
adjuvant according to the manufacturer’s recommendation (1 : 1
ratio). Five cattle housed at the high-containment isolation facility
of The Pirbright Institute, Pirbright, UK, were used for serum
production. All the animals were sero-negative for FMDV antibodies
at the beginning of the experiment. The animals were observed for
7 days before the beginning of the experiment to make sure that they
were in good health. The animals were injected subcutaneously with
1 ml of an emulsion containing 15 mg each of the recombinant viral
antigen. All the animals received a booster at 21 days post-vaccination
and were bled 1 week later for serum preparation. The serum was
stored at 220 uC until use. A pool of sera from five animals was used
for serological tests.
Virus neutralization test. The 2D-VNT was carried out using the
pooled 28th day post-vaccination bovine sera from five animals to
determine the sero-reactivity of the mutant viruses according to
Rweyemamu et al. (1978). The recombinant virus, rO1K/A-EA-2007,
was used as the homologous virus in the VN test. Antibody titres were
calculated from regression data as the log10 reciprocal antibody
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dilution required for 50% neutralization of 100 tissue culture
infective units of virus (log10SN50/100 TCID50). The antigenic
relationship of a mutant virus to its parent is given by the ratio:
‘r1’5neutralizing antibody titre against the mutant virus/neutralizing
antibody titre against the recombinant parental virus. The significance
of differences between ‘r1-values’ obtained by the polyclonal serum
was evaluated according to the method of Rweyemamu & Hingley
(1984) using a cut-off r1-value¢0.3 as representing an expectation of
adequate cross protection. Each test was conducted in duplicate and
repeated at least eight times. Test results showing evidence of a
reduction in serum titre after mutagenesis were repeated eight more
times for further confirmation.
Data analysis. The data were analysed using MINITAB (version 16)
software. A paired t-test was used to compare the differences in sero-
reactivity between the homologous and the mutant viruses.
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